297 related articles for article (PubMed ID: 21403679)
41. Epithelial-mesenchymal transition-related gene expression as a new prognostic marker for neuroblastoma.
Nozato M; Kaneko S; Nakagawara A; Komuro H
Int J Oncol; 2013 Jan; 42(1):134-40. PubMed ID: 23135478
[TBL] [Abstract][Full Text] [Related]
42. In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts.
Joseph JM; Gross N; Lassau N; Rouffiac V; Opolon P; Laudani L; Auderset K; Geay JF; Mühlethaler-Mottet A; Vassal G
Int J Cancer; 2005 Mar; 113(6):881-90. PubMed ID: 15514941
[TBL] [Abstract][Full Text] [Related]
43. Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells.
Nardella M; Guglielmi L; Musa C; Iannetti I; Maresca G; Amendola D; Porru M; Carico E; Sessa G; Camerlingo R; Dominici C; Megiorni F; Milan M; Bearzi C; Rizzi R; Pirozzi G; Leonetti C; Bucci B; Mercanti D; Felsani A; D'Agnano I
Oncotarget; 2015 Oct; 6(32):32821-40. PubMed ID: 26439802
[TBL] [Abstract][Full Text] [Related]
44. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
45. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
[TBL] [Abstract][Full Text] [Related]
46. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma.
Marcus K; Johnson M; Adam RM; O'Reilly MS; Donovan M; Atala A; Freeman MR; Soker S
Neuropathology; 2005 Sep; 25(3):178-87. PubMed ID: 16193833
[TBL] [Abstract][Full Text] [Related]
47. Characterization of in vivo chemoresistant human hepatocellular carcinoma cells with transendothelial differentiation capacities.
Marfels C; Hoehn M; Wagner E; Günther M
BMC Cancer; 2013 Apr; 13():176. PubMed ID: 23547746
[TBL] [Abstract][Full Text] [Related]
48.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
49. Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.
Villasante A; Sakaguchi K; Kim J; Cheung NK; Nakayama M; Parsa H; Okano T; Shimizu T; Vunjak-Novakovic G
Theranostics; 2017; 7(17):4099-4117. PubMed ID: 29158813
[TBL] [Abstract][Full Text] [Related]
50. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
[TBL] [Abstract][Full Text] [Related]
51. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
52. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
[TBL] [Abstract][Full Text] [Related]
53. Tenascin-C is involved in promotion of cancer stemness via the Akt/HIF1ɑ axis in esophageal squamous cell carcinoma.
Yang Z; Zhang C; Feng Y; Qi W; Cui Y; Xuan Y
Exp Mol Pathol; 2019 Aug; 109():104239. PubMed ID: 30904401
[TBL] [Abstract][Full Text] [Related]
54. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
56. Molecularly guided therapy of neuroblastoma: a review of different approaches.
Tonini GP; Pistoia V
Curr Pharm Des; 2006; 12(18):2303-17. PubMed ID: 16787256
[TBL] [Abstract][Full Text] [Related]
57. Prokineticin signaling is required for the maintenance of a de novo population of c-KIT⁺ cells to sustain neuroblastoma progression.
Lau ST; Hansford LM; Chan WK; Chan GC; Wan TS; Wong KK; Kaplan DR; Tam PK; Ngan ES
Oncogene; 2015 Feb; 34(8):1019-34. PubMed ID: 24632619
[TBL] [Abstract][Full Text] [Related]
58. Binomial mitotic segregation of MYCN-carrying double minutes in neuroblastoma illustrates the role of randomness in oncogene amplification.
Lundberg G; Rosengren AH; Håkanson U; Stewénius H; Jin Y; Stewénius Y; Påhlman S; Gisselsson D
PLoS One; 2008 Aug; 3(8):e3099. PubMed ID: 18769732
[TBL] [Abstract][Full Text] [Related]
59. Krüppel-like factor 4 (KLF4) suppresses neuroblastoma cell growth and determines non-tumorigenic lineage differentiation.
Shum CK; Lau ST; Tsoi LL; Chan LK; Yam JW; Ohira M; Nakagawara A; Tam PK; Ngan ES
Oncogene; 2013 Aug; 32(35):4086-99. PubMed ID: 23045286
[TBL] [Abstract][Full Text] [Related]
60. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.
Eggert A; Ikegaki N; Kwiatkowski J; Zhao H; Brodeur GM; Himelstein BP
Clin Cancer Res; 2000 May; 6(5):1900-8. PubMed ID: 10815914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
